TW200418834A - Indolyl pyrazinone derivatives useful for treating hyper-proliferative disorders - Google Patents
Indolyl pyrazinone derivatives useful for treating hyper-proliferative disorders Download PDFInfo
- Publication number
- TW200418834A TW200418834A TW092131443A TW92131443A TW200418834A TW 200418834 A TW200418834 A TW 200418834A TW 092131443 A TW092131443 A TW 092131443A TW 92131443 A TW92131443 A TW 92131443A TW 200418834 A TW200418834 A TW 200418834A
- Authority
- TW
- Taiwan
- Prior art keywords
- alkyl
- crc3
- alkoxy
- phenyl
- independently selected
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US42549002P | 2002-11-12 | 2002-11-12 | |
| US46091503P | 2003-04-07 | 2003-04-07 | |
| US48420203P | 2003-06-30 | 2003-06-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW200418834A true TW200418834A (en) | 2004-10-01 |
Family
ID=32314888
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW092131443A TW200418834A (en) | 2002-11-12 | 2003-11-11 | Indolyl pyrazinone derivatives useful for treating hyper-proliferative disorders |
Country Status (17)
| Country | Link |
|---|---|
| EP (1) | EP1565455A1 (fr) |
| JP (1) | JP2006509840A (fr) |
| KR (1) | KR20050072824A (fr) |
| AR (1) | AR043059A1 (fr) |
| AU (1) | AU2003290744A1 (fr) |
| BR (1) | BR0316169A (fr) |
| CA (1) | CA2505819A1 (fr) |
| EC (1) | ECSP055851A (fr) |
| HR (1) | HRP20050496A2 (fr) |
| MA (1) | MA27557A1 (fr) |
| MX (1) | MXPA05004779A (fr) |
| NO (1) | NO20052796L (fr) |
| PE (1) | PE20040832A1 (fr) |
| PL (1) | PL376867A1 (fr) |
| TW (1) | TW200418834A (fr) |
| UY (1) | UY28074A1 (fr) |
| WO (1) | WO2004043950A1 (fr) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8614318B2 (en) | 2003-11-13 | 2013-12-24 | Abbvie Inc. | Apoptosis promoters |
| WO2005049593A2 (fr) * | 2003-11-13 | 2005-06-02 | Abbott Laboratories | Promoteurs de l'apoptose contenant n-acylsulfonamide |
| US7973161B2 (en) | 2003-11-13 | 2011-07-05 | Abbott Laboratories | Apoptosis promoters |
| US7767684B2 (en) | 2003-11-13 | 2010-08-03 | Abbott Laboratories | Apoptosis promoters |
| US7928104B2 (en) | 2003-11-20 | 2011-04-19 | Dominique Jean-Pierre Mabire | 7-phenylalkyl substituted 2-quinolinones and 2-quinoxalinones as poly(ADP-ribose) polymerase inhibitors |
| WO2005054201A1 (fr) | 2003-11-20 | 2005-06-16 | Janssen Pharmaceutica N.V. | 2-quinolinones et 2-quinoxalinones substituees par 6-alcenyle et 6-phenylalkyle utilisees comme inhibiteurs de la poly(adp-ribose) polymerase (parp) |
| CA2545478A1 (fr) * | 2003-11-21 | 2005-06-09 | Bayer Pharmaceuticals Corporation | Derives d'indolyl-thieno`3,4-b!pyrazin-3-one utilises pour traiter les maladies et les troubles hyper-proliferatifs associes a l'angiogenese |
| US7459562B2 (en) * | 2004-04-23 | 2008-12-02 | Bristol-Myers Squibb Company | Monocyclic heterocycles as kinase inhibitors |
| EA014955B1 (ru) | 2004-06-30 | 2011-04-29 | Янссен Фармацевтика Н. В. | Производные фталазина в качестве ингибиторов parp |
| UA88012C2 (uk) | 2004-06-30 | 2009-09-10 | Янссен Фармацевтика Н.В. | Похідні хіназоліндіону як інгібітори parp |
| ATE498613T1 (de) | 2004-06-30 | 2011-03-15 | Janssen Pharmaceutica Nv | Chinazolinonderivate als parp-hemmer |
| DE602005026557D1 (de) | 2004-11-17 | 2011-04-07 | Korea Res Inst Chem Tech | 1-ä(6-substituiertes alkoxychinoxalinyl) aminocarbonylü-4-(hetero)arylpiperazinderivate |
| PT1888550E (pt) | 2005-05-12 | 2014-09-03 | Abbvie Bahamas Ltd | Promotores de apoptose |
| US8624027B2 (en) | 2005-05-12 | 2014-01-07 | Abbvie Inc. | Combination therapy for treating cancer and diagnostic assays for use therein |
| US8492378B2 (en) | 2006-08-03 | 2013-07-23 | Takeda Pharmaceutical Company Limited | GSK-3β inhibitor |
| US7897762B2 (en) * | 2006-09-14 | 2011-03-01 | Deciphera Pharmaceuticals, Llc | Kinase inhibitors useful for the treatment of proliferative diseases |
| EP2134691B1 (fr) | 2007-03-08 | 2012-01-25 | Janssen Pharmaceutica, N.V. | Dérivés de quinolinone comme inhibiteurs de parp et de tank |
| WO2009118382A1 (fr) | 2008-03-27 | 2009-10-01 | Janssen Pharmaceutica Nv | Tétrahydrophénanthridinones et tétrahydrocyclopentaquinolinones comme inhibiteurs de la polymérisation de la tubuline et de parp |
| WO2010053757A1 (fr) | 2008-10-29 | 2010-05-14 | Gilead Palo Alto, Inc. | Inhibiteurs, à base de 2-oxoquinoxaline, des canaux sodiques tardifs |
| WO2010074807A1 (fr) | 2008-10-30 | 2010-07-01 | Gilead Palo Alto, Inc. | Dérivés 3, 4-dihydroquinolin-2 (1h) -one utilisés comme modulateurs de canaux sodiques |
| EP2352725A1 (fr) * | 2008-11-07 | 2011-08-10 | Wyeth LLC | Modulateurs de lxr à base de quinoxaline |
| US20100160322A1 (en) | 2008-12-04 | 2010-06-24 | Abbott Laboratories | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
| US8557983B2 (en) | 2008-12-04 | 2013-10-15 | Abbvie Inc. | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
| US8563735B2 (en) | 2008-12-05 | 2013-10-22 | Abbvie Inc. | Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases |
| US8586754B2 (en) | 2008-12-05 | 2013-11-19 | Abbvie Inc. | BCL-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases |
| GB201007286D0 (en) | 2010-04-30 | 2010-06-16 | Astex Therapeutics Ltd | New compounds |
| GB201020179D0 (en) | 2010-11-29 | 2011-01-12 | Astex Therapeutics Ltd | New compounds |
| GB201118675D0 (en) | 2011-10-28 | 2011-12-14 | Astex Therapeutics Ltd | New compounds |
| GB201118656D0 (en) | 2011-10-28 | 2011-12-07 | Astex Therapeutics Ltd | New compounds |
| GB201118652D0 (en) | 2011-10-28 | 2011-12-07 | Astex Therapeutics Ltd | New compounds |
| GB201118654D0 (en) | 2011-10-28 | 2011-12-07 | Astex Therapeutics Ltd | New compounds |
| GB201209609D0 (en) | 2012-05-30 | 2012-07-11 | Astex Therapeutics Ltd | New compounds |
| GB201209613D0 (en) | 2012-05-30 | 2012-07-11 | Astex Therapeutics Ltd | New compounds |
| GB201307577D0 (en) | 2013-04-26 | 2013-06-12 | Astex Therapeutics Ltd | New compounds |
| HUE053654T2 (hu) | 2014-03-26 | 2021-07-28 | Astex Therapeutics Ltd | FGFR- és CMET-inhibitorok kombinációi a rák kezelésére |
| JO3512B1 (ar) | 2014-03-26 | 2020-07-05 | Astex Therapeutics Ltd | مشتقات كينوكسالين مفيدة كمعدلات لإنزيم fgfr كيناز |
| JP6980385B2 (ja) | 2014-03-26 | 2021-12-15 | アステックス、セラピューティックス、リミテッドAstex Therapeutics Limited | Ｆｇｆｒ阻害剤とｉｇｆ１ｒ阻害剤の組合せ |
| TW201625578A (zh) * | 2014-04-18 | 2016-07-16 | 千禧製藥公司 | 喹啉化合物及其用途 |
| WO2016118565A1 (fr) | 2015-01-20 | 2016-07-28 | Millennium Pharmaceuticals, Inc. | Composés quinazoline et quinoléine, et utilisations de ceux-ci |
| JOP20200201A1 (ar) | 2015-02-10 | 2017-06-16 | Astex Therapeutics Ltd | تركيبات صيدلانية تشتمل على n-(3.5- ثنائي ميثوكسي فينيل)-n'-(1-ميثيل إيثيل)-n-[3-(ميثيل-1h-بيرازول-4-يل) كينوكسالين-6-يل]إيثان-1.2-ثنائي الأمين |
| US10478494B2 (en) | 2015-04-03 | 2019-11-19 | Astex Therapeutics Ltd | FGFR/PD-1 combination therapy for the treatment of cancer |
| BR112018005637B1 (pt) | 2015-09-23 | 2023-11-28 | Janssen Pharmaceutica Nv | Compostos derivados de quinoxalina, quinolina e quinazolinona,composições farmacêuticas que os compreende, e uso dos referidos compostos |
| KR20180052631A (ko) | 2015-09-23 | 2018-05-18 | 얀센 파마슈티카 엔.브이. | 비-헤테로아릴 치환된 1,4-벤조디아제핀 및 암의 치료를 위한 이의 용도 |
| TW202317086A (zh) * | 2021-09-29 | 2023-05-01 | 加拿大商修復治療公司 | 化合物、醫藥組成物及製備化合物之方法及其使用方法 |
| WO2024069592A1 (fr) * | 2022-09-29 | 2024-04-04 | Repare Therapeutics Inc. | Composés de n-([(l, 3,4-thiadiazolyle) substitué en position 5 ou (l,3-thiazolyl)](substitué)carboxamide, compositions pharmaceutiques et procédés de préparation de composés amides et leur utilisation |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW472045B (en) * | 1996-09-25 | 2002-01-11 | Astra Ab | Protein kinase C inhibitor compounds, method for their preparation, pharmaceutical composition thereof and intermediate used for their preparation |
| AU1918299A (en) * | 1998-02-23 | 1999-09-06 | Warner-Lambert Company | Substituted quinoxaline derivatives as interleukin-8 receptor antagonists |
-
2003
- 2003-11-05 AR ARP030104059A patent/AR043059A1/es unknown
- 2003-11-10 KR KR1020057008396A patent/KR20050072824A/ko not_active Application Discontinuation
- 2003-11-10 WO PCT/US2003/036003 patent/WO2004043950A1/fr active Application Filing
- 2003-11-10 JP JP2005507146A patent/JP2006509840A/ja active Pending
- 2003-11-10 MX MXPA05004779A patent/MXPA05004779A/es not_active Application Discontinuation
- 2003-11-10 BR BR0316169-2A patent/BR0316169A/pt not_active Application Discontinuation
- 2003-11-10 EP EP03783328A patent/EP1565455A1/fr not_active Withdrawn
- 2003-11-10 PL PL376867A patent/PL376867A1/pl unknown
- 2003-11-10 CA CA002505819A patent/CA2505819A1/fr not_active Abandoned
- 2003-11-10 AU AU2003290744A patent/AU2003290744A1/en not_active Abandoned
- 2003-11-11 UY UY28074A patent/UY28074A1/es not_active Application Discontinuation
- 2003-11-11 PE PE2003001136A patent/PE20040832A1/es not_active Application Discontinuation
- 2003-11-11 TW TW092131443A patent/TW200418834A/zh unknown
-
2005
- 2005-06-02 HR HR20050496A patent/HRP20050496A2/hr not_active Application Discontinuation
- 2005-06-09 NO NO20052796A patent/NO20052796L/no not_active Application Discontinuation
- 2005-06-09 MA MA28322A patent/MA27557A1/fr unknown
- 2005-06-10 EC EC2005005851A patent/ECSP055851A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| HRP20050496A2 (en) | 2006-06-30 |
| BR0316169A (pt) | 2005-09-27 |
| UY28074A1 (es) | 2004-05-31 |
| PL376867A1 (pl) | 2006-01-09 |
| EP1565455A1 (fr) | 2005-08-24 |
| CA2505819A1 (fr) | 2004-05-27 |
| ECSP055851A (es) | 2005-09-20 |
| AR043059A1 (es) | 2005-07-13 |
| MXPA05004779A (es) | 2005-07-22 |
| PE20040832A1 (es) | 2005-01-27 |
| JP2006509840A (ja) | 2006-03-23 |
| NO20052796D0 (no) | 2005-06-09 |
| KR20050072824A (ko) | 2005-07-12 |
| MA27557A1 (fr) | 2005-10-03 |
| AU2003290744A1 (en) | 2004-06-03 |
| NO20052796L (no) | 2005-06-09 |
| WO2004043950A1 (fr) | 2004-05-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TW200418834A (en) | Indolyl pyrazinone derivatives useful for treating hyper-proliferative disorders | |
| RU2682245C1 (ru) | Индазольные ингибиторы сигнального пути wnt и их терапевтические применения | |
| US20220106321A1 (en) | Viral replication inhibitors | |
| AU2007279166C1 (en) | N-(aminoheteroaryl)-1H-indole-2-carboxamide derivatives, preparation thereof and therapeutic use thereof | |
| AU2001259190B2 (en) | Muscarinic agonists | |
| KR101586112B1 (ko) | 카바졸 화합물 및 이 화합물의 치료학적 용도 | |
| US20070043057A1 (en) | Lonidamine analogs | |
| CN106458934B (zh) | 喹喔啉化合物及其用途 | |
| ES2353309T3 (es) | Hidrazidas del ácido pirrolopiridin-2-carboxílico como inhibidores de glucógeno fosforilasa. | |
| US20070015771A1 (en) | Lonidamine analogs | |
| KR101288698B1 (ko) | Ｎ-(헤테로아릴)-１ｈ-인돌-2-카르복스아미드 유도체 및바닐로이드 ｔｒｐｖ１ 수용체 리간드로서의 그의 용도 | |
| CN104341425B (zh) | 氘代乙炔衍生物、其药物组合物及应用 | |
| TW201036958A (en) | Pyridazinone compounds | |
| TW200819131A (en) | N-(1-hetarylpiperidin-4-yl)(het)arylamides as EP2 receptor modulators | |
| CA2637333A1 (fr) | Derives de n-heteroaryl-carboxamides tricycliques contenant un motif benzimidazole, leur preparation et leur application en therapeutique | |
| TWI386407B (zh) | Ｎ-（芳烷基）-１ｈ-吡咯并吡啶-２-羧醯胺衍生物，其製備及其治療用途 | |
| ES2687475T3 (es) | Nuevos derivados de indol y de pirrol, su procedimiento de preparación y las composiciones farmacéuticas que los contienen | |
| US20090093476A1 (en) | Pyrrolo[1,2-a]quinoxaline derivatives as adenosine a3 receptor modulators and uses thereof | |
| KR20160073413A (ko) | 퀴나졸리논 및 이소퀴놀리논 유도체 | |
| ES2304546T3 (es) | Derivados de priridoindolona sustituidos en la posicion 3 con un fenilo, su preparacion y su aplicacion en terapeutica. | |
| BR112021000857A2 (pt) | Derivados adicionais substituídos de triazolo quinoxalina | |
| ES2747423T3 (es) | Compuesto de quinoxalina | |
| TW479058B (en) | 2,7-substituted octahydro-pyrrolo[1,2-a]pyrazine derivatives | |
| US8258168B2 (en) | 2H or 3H-benzo[E]indazol-1-YL carbamate derivatives, the preparation and therapeutic use thereof | |
| ES2492694T3 (es) | Nuevos compuestos espiroheterocíclicos como antagonistas de mGlu5 |